April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Ctla-2 Alpha Is Potent Inhibitor Of Angiogenesis In Murin Ocular Tissue
Author Affiliations & Notes
  • Kazuichi Maruyama
    Ophthalmology, Kyoto Prefectural Univ of Med, Kamigyo-ku, Japan
  • Sunao Sugita
    Dept of Ophthalmology, Tokyo Medical & Dental Univ, Tokyo, Japan
  • Kazuhito Yoneda
    Ophthalmology, Kyoto Prefectural Univ of Med, Kamigyo-ku, Japan
  • Shigeru Kinoshita
    Ophthalmology, Kyoto Prefectural Univ of Med, Kamigyo-Ku, Japan
  • Footnotes
    Commercial Relationships  Kazuichi Maruyama, None; Sunao Sugita, None; Kazuhito Yoneda, None; Shigeru Kinoshita, None
  • Footnotes
    Support  KAKEN FY2010
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6403. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kazuichi Maruyama, Sunao Sugita, Kazuhito Yoneda, Shigeru Kinoshita; Ctla-2 Alpha Is Potent Inhibitor Of Angiogenesis In Murin Ocular Tissue. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6403.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Ocular tissue such as corneal epithelial cell and retinal pigment epithelial cell has the ability to inhibit the neo-vascularization spontaneously. We confirmed that an immune-regulatory factor such as Cytotoxic T lymphocyte antigen-2 (CTLA-2)-alpha was specifically expressed in the corneal epithelial and endothelial layers and in retinal pigment epithelia by the use of in situ hybridization and immunohistochemistry. The purpose of this present study was to investigate whether CTLA-2 alpha might also have the ability of controlling anti-angiogenesis in vivo.

Methods: : Male C57BL/6 mice (8-10 weeks old) were used for all experiments. For a model of corneal inflammation, stromal incisions that encompassed more than 120 degrees of the corneal circumference were made and three 11-0 nylon sutures were then placed intrastromally (each group, n=5). Recombinant CTLA-2 alpha (1µg) (n=5) was injected into the peritoneal cavity at 0, 3, and 5 days after suture placement. Also, we performed laser-induced choroidal neovascularization (CNV) by using CTLA-2 alpha treatment (at day 0, 3, 5, 7, 9, 11, and 13). At day14 after laser treatment, the area of CNV was measured.

Results: : he three-time peritoneal cavity injection of CTLA-2 alpha was found to suppress both corneal angiogenesis (p=0.0357) and CNV (p=0.01). Moreover, the low dose of CTLA-2 alpha inhibited the proliferation of vascular endothelial cells in vitro and their function was ceased by the neutralizing antibody.

Conclusions: : The findings of this present study show that CTLA-2 alpha has the mobility of suppressing angiogenesis. Further development of CTLA-2 alpha may prove it to be a new anti-angiogeneic factor that could used to treat various diseases and tumor progression.

Keywords: cornea: basic science 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.